CYTOSORBENTS CORPORATION Income (Loss) from Continuing Operations before Income Taxes, Domestic
CYTOSORBENTS CORPORATION (CTSO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$9.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-30
- CYTOSORBENTS CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$9.61M.
- CYTOSORBENTS CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$11.72M.
- CYTOSORBENTS CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$21.91M.
- CYTOSORBENTS CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$21.16M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$9.61M 10-K · filed 2026-03-30 | |
| 2024-12-31 | -$11.72M 10-K · filed 2026-03-30 | -$11.72M 10-K · filed 2025-03-31 |
| 2023-12-31 | -$21.91M 10-K · filed 2025-03-31 | -$21.48M 10-K · filed 2024-03-15 |
| 2022-12-31 | -$21.16M 10-K · filed 2024-03-15 | |
| 2021-12-31 | -$18.83M 10-K · filed 2024-03-15 | |
| 2020-12-31 | -$5.68M 10-K · filed 2023-03-09 | |
| 2019-12-31 | -$11.92M 10-K · filed 2022-03-10 | -$11.29M 10-K · filed 2020-03-05 |
| 2018-12-31 | -$14.11M 10-K · filed 2021-03-09 | |
| 2017-12-31 | -$6.07M 10-K · filed 2020-03-05 | |
| 2016-12-31 | -$9.30M 10-K · filed 2019-03-07 | -$9.48M 10-K · filed 2017-03-03 |
| 2015-12-31 | -$6.85M 10-K · filed 2018-03-08 | -$8.46M 10-K · filed 2016-03-09 |
| 2014-12-31 | -$6.48M 10-K · filed 2017-03-03 | -$9.71M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |